This study showed that higher expression of NFE2L3 had poorer prognosis for OS in six tumor types, including KIRC, KIRP, brain lower grade glioma (LGG), LIHC, mesothelioma (MESO), and pancreatic adenocarcinoma (PAAD). Here, NFE2L3 is linked to neoplasm.